

**CLAIM AMENDMENTS**

275. (currently amended) A multimeric composition comprising more than one monomeric unit, said monomeric unit comprising two elements, wherein said first element is (a) a protein, selected from the group consisting of an antibody, a lymphokine, a cytokine, a hormone, a cellular matrix protein, and a receptor binding protein ~~and a growth factor~~ and said second element is (b) a polymer, selected from the group consisting of a polynucleotide and a polysaccharide and wherein said monomeric units are attached to a binding matrix through said second element via noncovalent polymeric interactions selected from the group consisting of hydrogen bonding and dipole interactions and combinations thereof, between said polymer of said monomeric unit and said polymer of said binding matrix, wherein said binding matrix is selected from the group consisting of a polypeptide, polynucleotide or polysaccharide or any combination thereof.

Claims 276-282 (canceled)

283. (previously presented) The composition of claim 275, wherein more than one protein of the first element of said monomeric unit is attached to the polymer of said second element of said monomeric unit.

284. (currently amended) The composition according to claim 275 291 wherein said hormone is insulin.

285. (currently amended) The composition according to claim 275 294, wherein said growth factor is erythropoietin.

286. (previously presented) The composition according to claim 275, wherein said cellular matrix protein is fibronectin.

287. (previously presented) The composition according to claim 275, wherein said polypeptide is protamine, polyglutamic acid or polylysine.

288. (previously presented) The composition according to claim 275, wherein said polysaccharide is soluble DEAE, dextran sulfate, carboxymethyl cellulose or DEAE dextran.

289. (withdrawn) A process for delivering the multimeric complex of claim 275 to a subject comprising introducing the complex to one or more cells ex vivo and administering said cells to said subject.

290. (withdrawn) A process for delivering the multimeric complex of claim 275 to a subject comprising administering said complex to said subject.

291. (new) The composition according to claim 275, wherein said receptor binding protein is a hormone.

292. (new) The composition according to claim 275, wherein said receptor binding protein is a cytokine.

293. (new) The composition according to claim 292, wherein said cytokine is a lymphokine.

294. (new) The composition according to claim 275, wherein said receptor binding protein is a growth factor.

295. (new) The composition according to claim 275, wherein said second element is a polynucleotide and wherein said monomeric units are attached to a binding matrix through said second element via hydrogen bonding between said polymer of said monomeric unit and said binding matrix, wherein said binding matrix is a polynucleotide.